Q-LINE BIOTECH LIMITED (QLINE-SM) Share Price Rises 8.4% Today

Q-LINE BIOTECH LIMITED Share Price Today rose 8.4% to Rs 555, lifting market capitalisation to Rs 1,204.2 crore as the stock featured among notable small-cap gainers on NSE.

Q-LINE BIOTECH LIMITED Share Price moved up to Rs 555 on 21 August 2026, rising 8.4% from the previous close of Rs 512 and taking the company’s market capitalisation to Rs 1,204.2 crore. That puts Q-LINE BIOTECH LIMITED Share Price firmly in focus in today’s Stock Market Today session, especially because the move was captured by a market-cap based price rise screen for the Small Cap category.

For investors searching Q-LINE BIOTECH LIMITED Share Price Today, the verified data shows a clear single-day gain supported by NSE volume of 94,400 shares and turnover of Rs 5.24 crore. The stock opened at Rs 510, traded between Rs 508.1 and Rs 558.9, and held most of the day’s advance near the upper end of that intraday range. The supplied data confirms the price event, but it does not establish a company-specific catalyst behind the move.

That distinction matters. In Q-LINE BIOTECH LIMITED Stock News, what is verified today is the share price rise, the size of the move, the trading range, the company’s valuation ratios, and its position within the Healthcare sector’s Medical Equipment/Supplies/Accessories industry. Investors following Q-LINE BIOTECH LIMITED Share Price are therefore likely to watch three things next: whether price action sustains after today’s top gainer appearance, how the valuation compares with peers, and whether profitability metrics such as ROE and ROCE continue to justify investor attention. In this Univest stock analysis, the emphasis stays on facts, not assumptions.

Q-LINE BIOTECH LIMITED (QLINE-SM) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 555
Previous Close	Rs 512
Today's Change	+Rs 43 (+8.4%)
Day Open	Rs 510
Day High	Rs 558.9
Day Low	Rs 508.1
Current Volume (NSE)	94,400
NSE Traded Volume	94,400
Combined NSE + BSE Volume	94,400
Turnover	Rs 5.24 crore
Market Capitalisation	Rs 1,204.2 crore
Market Cap Category	Small Cap

Q-LINE BIOTECH LIMITED (QLINE-SM) traded at Rs 555. versus the previous close of Rs 512, a rise of 8.4%. The stock opened at Rs 510, reached Rs 558.9, touched Rs 508.1. Reported volume was 94,400.

Q-LINE BIOTECH LIMITED (QLINE-SM) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 1,204.2 crore
P/E Ratio	21.44x
P/B Ratio	5.64x
ROE	16.79%
ROCE	16.76%
EPS	Rs 23.89
Dividend Yield	0%

Q-LINE BIOTECH LIMITED was valued at a P/E ratio of 21.44x, a P/B ratio of 5.64x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 16.79% and ROCE of 16.76%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 23.89, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Q-LINE BIOTECH LIMITED Share Price is drawing attention today, but the financial ratios help explain whether the market is watching a business with measurable profitability and a defined valuation profile. The supplied numbers show a profitable small-cap healthcare company trading at moderate earnings multiples relative to several peers, though not at a low price-to-book multiple.

From a valuation perspective, Q-LINE BIOTECH LIMITED Share Price implies a P/E ratio of 21.44 and a P/B ratio of 5.64. Those two numbers should be read together. The P/E ratio indicates the stock trades at 21.44 times earnings, while the P/B ratio shows investors are paying 5.64 times the accounting net worth carried on the balance sheet. In Q-LINE BIOTECH LIMITED Fundamental Analysis, that mix suggests the market is assigning a meaningful value to the business beyond book capital alone.

Profitability metrics are steady rather than extreme. Return on equity stands at 16.79%, and return on capital employed is 16.76%. That means the company is generating mid-teen returns on both shareholder equity and capital employed, figures that support the case for investor interest without implying exceptional outperformance on their own. EPS is Rs 23.89, which is the earnings attributable to each share and gives Q-LINE BIOTECH LIMITED Share Price a concrete earnings anchor. Dividend yield is 0, so the current valuation case in this stock analysis rests more on earnings and return ratios than on cash payout history.

Market capitalisation at Rs 1,204.2 crore places the company at the upper end of the supplied same-industry universe by size. That matters because Q-LINE BIOTECH LIMITED Market Cap is materially larger than the industry median market capitalisation of Rs 125.16 crore and above the industry average of Rs 315.33 crore. In other words, the stock is not merely rising today; it already sits at the top of the supplied market-cap range for this industry set.

The supplied data confirms the price rise, valuation and profitability snapshot, but it does not establish a company-specific operating trigger such as Q-LINE BIOTECH LIMITED Financial Results or earnings news. For investors reviewing Q-LINE BIOTECH LIMITED Share Price, today’s move therefore needs to be interpreted through valuation, quality and relative positioning within its healthcare niche. That naturally leads to the sector benchmark and peer set.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Medical Equipment/Supplies/Accessories
Benchmark Scope	same industry
Company P/E Ratio	21.44x
Benchmark Median P/E	26.71x
Benchmark Average P/E	88.91x
Benchmark P/E Range	8.21x to 1,121.12x
Company P/B Ratio	5.64x
Benchmark Median P/B	3.23x
Company ROE	16.79%
Benchmark Median ROE	15.31%
Company ROCE	16.76%
Benchmark Median ROCE	16.86%
Company Market Capitalisation	Rs 1,204.2 crore
Benchmark Median Market Cap	Rs 125.16 crore

Q-LINE BIOTECH LIMITED (QLINE-SM) is classified under sector: Healthcare and industry: Medical Equipment/Supplies/Accessories.

Q-LINE BIOTECH LIMITED (QLINE-SM) has a P/E ratio of 21.44x, which is below the benchmark median of 26.71x, a difference of -19.73%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Q-LINE BIOTECH LIMITED (QLINE-SM) has a ROE of 16.79%, which is above the benchmark median of 15.31%, a difference of +9.67%. Q-LINE BIOTECH LIMITED (QLINE-SM) has a ROCE of 16.76%, which is below the benchmark median of 16.86%, a difference of -0.59%.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Q-LINE BIOTECH LIMITED Share Price is best understood in the context of the Healthcare sector and the Medical Equipment/Supplies/Accessories industry, where benchmark data shows the company trades below the industry median P/E but above the median P/B. Its profitability profile is close to industry medians on ROE and ROCE, while its market capitalisation sits at the top end of the benchmark range.

The sector snapshot is based on the same industry and covers 20 companies. Within that universe, Q-LINE BIOTECH LIMITED Share Price reflects a company P/E of 21.44 against a median of 26.71 and an average of 88.91 across 19 companies with P/E data. The industry P/E range runs from 8.21 to 1121.12. On this comparison alone, Q-LINE BIOTECH LIMITED does not screen as richly valued on earnings versus the sector median, even though the broader average is heavily influenced by very high outliers.

The picture changes somewhat on book value multiples. Q-LINE BIOTECH LIMITED trades at a P/B of 5.64, above the same-industry median of 3.23 and average of 3.33, with the industry P/B range spanning 0.47 to 8.14 across 20 companies. That suggests investors are assigning a stronger balance-sheet multiple to the company than they are to the typical peer in this benchmark set.

Profitability is mixed relative to the benchmark. Q-LINE BIOTECH LIMITED ROE is 16.79%, which is above the median ROE of 15.31% but below the average of 23.37%. ROCE at 16.76% is just under the median ROCE of 16.86% and below the average of 25.13%. These are not weak numbers, but they do not place the company at the top of the industry on returns either.

Size is where the company clearly stands out. Q-LINE BIOTECH LIMITED Market Cap of Rs 1,204.2 crore exceeds the benchmark median of Rs 125.16 crore, the average of Rs 315.33 crore, and matches the maximum market capitalisation in the supplied universe. For anyone reading Q-LINE BIOTECH LIMITED Stock News, that means the stock’s place among Top Gainers Today comes from a company that is already one of the largest listed names in its specific industry sample, not a very small outlier.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
LAXMI DENTAL LIMITED	LAXMIDENTL	1,076.5	35.51	4.34	96.95	21.04
3B Blackbio Dx Ltd.	3BBLACKBIO	983.19	17.6	3.49	138.73	179.46
Osel Devices Ltd.	OSELDEVICE	683.58	23.37	6.24	27.16	16.95
Hemant Surgical Industries Ltd.	HSIL	505.69	27.31	3.45	13.84	14.34
Prevest Denpro Ltd.	PREVEST	474.78	21.49	3.58	38.13	46.96

Q-LINE BIOTECH LIMITED (QLINE-SM) has a P/E ratio of 21.44x compared with the displayed peer median of 23.37x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 16.79% compares with a peer median of 38.13% across the companies shown in the table. ROCE stood at 16.76% versus the displayed peer median of 21.04%, providing a capital-efficiency comparison. Q-LINE BIOTECH LIMITED (QLINE-SM) has a market capitalisation of Rs 1,204.2 crore. Among the 5 peers shown, 0 have a larger market capitalisation.

Q-LINE BIOTECH LIMITED Share Price also looks interesting when compared with individual listed peers. The peer set shows that the company sits near the top on market capitalisation, has a middle-range earnings multiple, and delivers return ratios that are respectable but generally below the strongest names in the industry.

Against LAXMI DENTAL LIMITED, Q-LINE BIOTECH LIMITED is larger by market capitalisation, at Rs 1,204.2 crore versus Rs 1,076.5 crore, while trading on a lower P/E of 21.44 versus 35.51. However, LAXMI DENTAL reports a much higher ROE of 96.95% and ROCE of 21.04%, which means the lower valuation for Q-LINE BIOTECH LIMITED comes with lower return metrics.

Compared with 3B Blackbio Dx Ltd., the contrast is sharper. 3B Blackbio has a lower P/E of 17.6 and far higher ROE of 138.73% and ROCE of 179.46%, though its market cap of Rs 983.19 crore is below Q-LINE BIOTECH LIMITED. Osel Devices Ltd. trades closer on valuation, with a P/E of 23.37 and P/B of 6.24, while posting ROE of 27.16% and ROCE of 16.95% on a smaller market cap of Rs 683.58 crore.

Hemant Surgical Industries Ltd. and Prevest Denpro Ltd. offer two different comparisons. Hemant Surgical trades at a higher P/E of 27.31 but lower ROE of 13.84% and ROCE of 14.34%, which makes Q-LINE BIOTECH LIMITED look stronger on returns while still being much larger. Prevest Denpro is almost identical on P/E at 21.49, but its ROE of 38.13% and ROCE of 46.96% are much higher despite a smaller market cap of Rs 474.78 crore.

Nureca Ltd., Yash Optics & Lens Ltd., Earkart Ltd. and AVIENCE BIOMEDICALS LTD further show that Q-LINE BIOTECH LIMITED Share Price is neither the cheapest nor the most expensive stock in the peer pack. Its P/E is below Nureca’s 70.89, Yash Optics’ 29.97 and Earkart’s 36.11, but above AVIENCE’s 15.04. Overall, the peer comparison suggests that today’s Q-LINE BIOTECH LIMITED Share Price Rise is occurring in a company with scale leadership in the peer set, moderate earnings valuation, and return ratios that are credible but not dominant.

Why Investors Are Watching Q-LINE BIOTECH LIMITED

Q-LINE BIOTECH LIMITED Share Price has moved into focus because today’s gain was large enough to qualify on a same-day price rise screen, while the underlying financial profile offers a measurable benchmark for investors. The stock combines a notable single-session move with a healthcare industry valuation that is below median on P/E, above median on P/B, and backed by mid-teen return ratios.

• Verified price action: the stock rose 8.4% to Rs 555 from Rs 512, after trading between Rs 508.1 and Rs 558.9.
• Trading participation: NSE volume was 94,400 shares with turnover of Rs 5.24 crore.
• Fundamental context: P/E stands at 21.44, P/B at 5.64, ROE at 16.79%, ROCE at 16.76%, EPS at Rs 23.89 and dividend yield at 0.
• Sector positioning: market capitalisation of Rs 1,204.2 crore is above the industry average and matches the top end of the supplied benchmark range.
• Relative valuation: the stock trades below the same-industry median P/E of 26.71 but above the median P/B of 3.23.

What investors may monitor next is whether Q-LINE BIOTECH LIMITED Share Price can sustain interest after today’s rally, whether subsequent Q-LINE BIOTECH LIMITED Latest News provides a company-specific explanation, and how its return ratios compare over time with peers such as Prevest Denpro, Osel Devices and 3B Blackbio. Univest is watching the stock mainly because the day’s move is clear, sizeable and backed by a visible industry context.

About Q-LINE BIOTECH LIMITED

Q-LINE BIOTECH LIMITED operates in the Healthcare sector and is classified within the Medical Equipment/Supplies/Accessories industry. Even with limited company-profile detail in the supplied dataset, that classification is useful for investors following Q-LINE BIOTECH LIMITED Share Price because it places the company within a specialised healthcare manufacturing and supply segment rather than the broader pharmaceuticals or hospital space.

The industry group itself includes listed businesses involved in medical equipment, diagnostic supplies, accessories and related healthcare products. Within that context, Q-LINE BIOTECH LIMITED is not a fringe listed company in the benchmark set. Its market capitalisation of Rs 1,204.2 crore is the highest value shown in the supplied same-industry snapshot, indicating that it already holds a meaningful listed footprint within this niche.

That scale matters when interpreting Q-LINE BIOTECH LIMITED Share News or Q-LINE BIOTECH LIMITED Company News. A stock in a specialised healthcare segment can attract attention not only from day traders reacting to price action, but also from investors comparing valuation, profitability and market position across peers. The company’s presence in the Medical Equipment/Supplies/Accessories basket means Q-LINE BIOTECH LIMITED Stock Performance is best judged against direct industry comparables rather than against the Healthcare sector as a whole.

For readers using Univest for Q-LINE BIOTECH LIMITED Stock Analysis, the practical takeaway is simple: this is a healthcare equipment-related listed company whose current market profile combines large relative size within its peer set, positive profitability ratios, and a valuation structure that sits below median on earnings but above median on book value.

Track Q-LINE BIOTECH LIMITED Share Price on Univest

Use Q-LINE BIOTECH LIMITED (QLINE-SM) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors who want to follow Q-LINE BIOTECH LIMITED Share Price more closely can use Univest to monitor live share price moves, market cap changes, valuation ratios, 52-week levels, and broader market insights in one place. For traders focused on Q-LINE BIOTECH LIMITED Share Price Today and for investors comparing Q-LINE BIOTECH LIMITED Fundamental Analysis with peers, a structured dashboard helps separate verified numbers from market noise.

On Univest, users can track Q-LINE BIOTECH LIMITED Share Price Live, review P/E, P/B, ROE, ROCE, EPS and dividend yield, compare the stock with peer companies in Healthcare, and watch how it features in screens such as top gainers or other Stock Updates. That makes Univest useful for monitoring both daily price action and longer-running sector context without turning a factual market update into a recommendation.

Frequently Asked Questions

What is Q-LINE BIOTECH LIMITED Share Price Today?

Ans. Q-LINE BIOTECH LIMITED Share Price Today was Rs 555 at the time of the update. The stock gained 8.4% or Rs 43 over the previous close of Rs 512, placing it among notable small-cap gainers on NSE.

Why is Q-LINE BIOTECH LIMITED rising today?

Ans. The supplied data confirms that Q-LINE BIOTECH LIMITED rose 8.4% in a single session and qualified on a price-rise screen for its market-cap category. However, the verified dataset does not establish any company-specific catalyst behind today’s move.

What were the day high and day low for Q-LINE BIOTECH LIMITED?

Ans. Q-LINE BIOTECH LIMITED traded between a day low of Rs 508.1 and a day high of Rs 558.9. The stock opened at Rs 510 and later moved close to the session high, reflecting firm intraday price action.

How much volume was traded in Q-LINE BIOTECH LIMITED today?

Ans. Q-LINE BIOTECH LIMITED recorded NSE volume of 94,400 shares, with total volume also at 94,400 shares. Turnover stood at Rs 5.24 crore, showing meaningful trading participation during the same session in which the stock gained 8.4%.

What is the market capitalisation of Q-LINE BIOTECH LIMITED?

Ans. Q-LINE BIOTECH LIMITED had a market capitalisation of Rs 1,204.2 crore in the supplied data. That places it in the Small Cap category in this workflow and at the top end of the supplied same-industry benchmark range.

Is Q-LINE BIOTECH LIMITED expensive based on P/E?

Ans. Q-LINE BIOTECH LIMITED trades at a P/E of 21.44. That is below the same-industry median P/E of 26.71 and well below the industry average of 88.91, though averages in this set are influenced by very high outliers.

How does Q-LINE BIOTECH LIMITED compare on P/B ratio?

Ans. Q-LINE BIOTECH LIMITED has a P/B ratio of 5.64. This is above the same-industry median of 3.23 and average of 3.33, indicating the stock trades at a stronger book-value multiple than many peers in the benchmark.

What do ROE and ROCE show for Q-LINE BIOTECH LIMITED?

Ans. Q-LINE BIOTECH LIMITED reported ROE of 16.79% and ROCE of 16.76%. Those figures are slightly above the industry median ROE of 15.31% and just below the median ROCE of 16.86% in the supplied comparison set.

What is the EPS and dividend yield of Q-LINE BIOTECH LIMITED?

Ans. Q-LINE BIOTECH LIMITED reported EPS of Rs 23.89 and dividend yield of 0. EPS shows earnings attributable to each share, while the zero dividend yield means the current dataset reflects no historical payout support in yield terms.

Which industry does Q-LINE BIOTECH LIMITED belong to?

Ans. Q-LINE BIOTECH LIMITED belongs to the Healthcare sector and the Medical Equipment/Supplies/Accessories industry. In the supplied benchmark of 20 same-industry companies, its market capitalisation of Rs 1,204.2 crore is the highest figure shown.